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The ¢eld of glycoconjugates (glycoproteins and
glycolipids) has had an image problem since 1865
when the association of carbohydrate with protein
was ¢rst demonstrated [1]. Biologists have certainly
been aware for a long time that oligosaccharides are
important. Glycogen and starch are recognized to be
major energy storage compounds and chitin, cellu-
lose and chondroitin sulfate to be major structural
components. However, although these functions were
considered to be essential for life, they lacked ‘intel-
ligence’ and could not match the excitement gener-
ated by proteins (with important functions in catal-
ysis, endocrinology, transport, signal transduction,
etc.) and by the information storage and transmis-
sion functions of the nucleic acids. It has frequently
been pointed out by experts in our ¢eld that oligo-
and polysaccharides have an enormous capacity for
information storage, e.g. the number of all possible
linear and branched isomers of a hexasaccharide was
calculated to be over 1.05U1012 [2], and more infor-
mation can be stored per unit molecular weight of
carbohydrate than by the other macromolecules, i.e.
‘more bang for the buck’. It has been estimated that
at least 500 genes (about 0.5^1.0% of the translated
human genome) probably participate in oligosac-
charide production and function [3]. To emphasize
the important biological roles of glycoconjugates,
glycoscientists have come up with terms like glycobi-
ology [4] and glycoimmunology [5]. These numerical
and salesmanship devices have apparently not im-
pressed the devotees of our sister macromolecules,
the proteins and nucleic acids. The reputation of gly-
cobiology was not helped by the fact that there were
almost as many postulated functions for glycoconju-
gates as there were structures, a point made in ele-
gant fashion by Ajit Varki in his article entitled ‘Bio-
logical roles of oligosaccharides: all of the theories
are correct’ [6].
A time-honoured mechanism for the demonstra-
tion of biological function has been the study of
human disease. In this respect, polysaccharides
have held their own, e.g. the glycogen storage and
lysosomal storage diseases, many of which pose very
serious clinical problems. However, these diseases in-
volve the abnormal accumulation and storage of var-
ious molecules, usually due to defective catabolism,
rather than primary defects in the more interesting
pathways essential for cell growth, anabolism, di¡er-
entiation, development, etc. Even I-cell disease (mu-
colipidosis II), caused by a defect in the biosynthetic
pathway leading to N-glycan synthesis, was lumped
into this general ‘storage disease’ category and did
not appear to alert non-glycoscientists to the impor-
tance of glycobiology.
For a variety of reasons, the above picture of be-
nign neglect has changed quite dramatically in the
past few years. As described in this special issue,
several important functions for glycoconjugates
have left the realm of conjecture and have become
established facts. For example, it has been shown
that lymphocyte homing and the leukocyte response
to an in£ammatory stimulus are mediated by the
binding of white cells to endothelial surfaces via a
protein-carbohydrate interaction involving selectins.
A defect in this interaction leads to leukocyte adhe-
sion de¢ciency type II. In a similar fashion, it ap-
pears that one of the mechanisms used by cancer
cells to invade distant tissues is via protein-carbohy-
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drate interactions. Bacteria also use interactions in-
volving carbohydrates to invade their hosts. The im-
portance of glycoconjugates for normal mammalian
development has received dramatic support from the
recent elucidation of the biochemical and genetic
causes of several subtypes of carbohydrate-de¢cient
glycoprotein syndrome and from the study of various
‘gene knock-out’ mouse mutants. These ¢ndings have
created great interest in the development of new ther-
apeutic agents that interfere with carbohydrate-based
interactions. It is therefore not surprising that there
has been a rapid increase in the number of ‘glyco-
based’ commercial enterprises.
This special issue reviews the present status of
many aspects of glycosylation and human disease.
Our coverage is not complete and other recent re-
views in this area are recommended [7^9].
Walter Morgan, working with Winifred Watkins,
illuminated the chemical basis of the human ABO
blood group system. Walter was born in 1900 and
was working at the bench until 1990. The editor ¢rst
met him in Ann Arbor, Michigan, at a conference
given in honour of his 65th birthday and saw him
again at many subsequent meetings. On the last oc-
casion, Walter was seen sight-seeing in Zurich at the
XIVth International Symposium on Glycoconjugates
in 1997. It is a great pleasure to dedicate the special
issue to this remarkable man.
The editor would like to thank J.R. Riordan, the
executive editor for ‘Molecular Basis of Disease’, for
the invitation to organize this volume, Pat Crowley
and Jane Kerr at Elsevier for their help and patience
and of course all the authors for their given time and
expertise to this project.
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